- Home
- Companies
- Theragenics
- Products
- Cesium Blu - Braided Suture Contains ...
Cesium Blu - Braided Suture Contains Seeds
Isoray’s Cesium Blu Braided Suture contains seeds loaded into a bioabsorbable and flexible suture that can be directly sewn into the affected tissues. The suture adds a unified structure to the seeds while maintaining flexibility. Common applications include use in the treatment of brain, colorectal, gynecological, and head and neck cancers.
- 9.7 day half-life
- Energy level at 30.4 Kev
- Faster dose delivery rate. 90% of dose delivered in ~33 days
- Detectable in the body for only 97 days
- Flexible suture allows for precise placement within tissue
- Bioabsorbable suitable for a range of body sites
- Customizable lengths available
- Expert Sales and Support teams ensuring real-time ordering and delivery for procedures throughout the body.
- Committed to offering interactive training programs throughout the US teaching the leading techniques and the newest tools.
- Empowering patients to make their own treatment decisions based on decades of data.
Not all brachytherapy radioisotopes are the same. Cesium Blu, Cs-131, offers you a powerful option for treating prostate and other cancers throughout the body.
Isoray’s proprietary isotope, Cesium Blu, has a higher energy allowing for a more uniform dose distribution with less overdosing than other permanent isotopes. (1)
Isoray’s proprietary isotope, Cesium Blu, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects. (2)
Isoray’s Cesium Blu proprietary permanent prostate cancer brachytherapy seeds allow for better dose homogeneity and the sparing of the urethra and rectum while providing comparable prostate coverage compared to other seeds with comparable or fewer seeds and needles. (3, 4, 5, 6)
Isoray’s proprietary isotope, Cesium Blu, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects. (7, 8, 9, 10)
Isoray’s Cesium Blu also delivers a higher “biological effective dose” or BED compared to I-125 or Pd-103 across a wide range of tumor types. (11)
Isoray along with investigators tracking PSA in both single arm and randomized prostate cancer treatment trials have concluded that Cesium Blu’s PSA response rates have similar early tumor control to I-125, which was previously considered the gold standard in permanent seed brachytherapy. (8, 12, 13)